| Price | 8.75p on 20-11-2025 at 19:25:05 |
|---|---|
| Change | 0.20p 2.33% |
| Buy | 9.50p |
| Sell | 8.00p |
| Last Trade: | Buy 40,000.00 at 8.80p |
| Day's Volume: | 385,321 |
| Last Close: | 8.80p |
| Open: | 8.80p |
| ISIN: | GB00B02LCQ05 |
| Day's Range | 8.60p - 9.00p |
| 52wk Range: | 5.00p - 9.00p |
| Market Capitalisation: | £540.45m |
| VWAP: | 8.638757p |
| Shares in Issue: | 6.14b |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Allergy Thera. (AGY) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 40,000 | 8.80p | Suspected BUY Trade |
16:35:20 - 20-Nov-25 |
| Buy* | 17,000 | 8.80p | Suspected BUY Trade |
14:00:16 - 20-Nov-25 |
| Sell* | 7,000 | 8.60p | Uncrossing Trade |
11:00:00 - 20-Nov-25 |
| Unknown* | 155,000 | 8.5222p | Ordinary |
10:58:54 - 20-Nov-25 |
| Buy* | 105 | 9.50p | SI Trade |
10:58:53 - 20-Nov-25 |
| Buy* | 185 | 9.50p | SI Trade |
10:58:53 - 20-Nov-25 |
| Sell* | 2,000 | 8.50p | SI Trade |
10:58:53 - 20-Nov-25 |
| Buy* | 10 | 9.50p | SI Trade |
10:58:53 - 20-Nov-25 |
| Buy* | 7,692 | 9.50p | SI Trade |
10:58:53 - 20-Nov-25 |
| Sell* | 200 | 8.50p | SI Trade |
10:58:53 - 20-Nov-25 |
Allergy Thera. (AGY) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 6th Nov 2025 7:22 am | RNS | Company to Evaluate Dual Listing on HKEX |
| 30th Oct 2025 7:00 am | RNS | G308 Phase III Year 2 Patient Screening Starts |
| 29th Oct 2025 7:00 am | RNS | Warrant Exercise and Paydown of Debt |
| 16th Oct 2025 7:00 am | RNS | Further progress in Phase I/IIa PROTECT trial |
| 31st Jul 2025 7:00 am | RNS-R | Grass MATA MPL Publications in Allergy Journal |
| 21st Jul 2025 7:00 am | RNS | Trading update for the year ended 30 June 2025 |
| 11th Jul 2025 7:00 am | RNS | PDMR Dealings |
| 13th Jun 2025 7:00 am | RNS-R | Allergy Therapeutics presents findings at EAACI |
| 10th Jun 2025 7:04 am | RNS-R | EAACI Early Career Research Award |
| 31st Mar 2025 7:00 am | RNS | Interim Results for six months ended 31 Dec 2024 |
